A Targetable Receptor Tyrosine Kinase in Metastatic Pheochromocytoma and Paraganglioma: A Future Journey for Anlotinib?
作者信息
Alkaissi Hussam, Pacak Karel
机构信息
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
J Endocr Soc. 2024 May 7;8(7):bvae092. doi: 10.1210/jendso/bvae092. eCollection 2024 May 23.
Abstract
摘要
相似文献
1
A Targetable Receptor Tyrosine Kinase in Metastatic Pheochromocytoma and Paraganglioma: A Future Journey for Anlotinib?转移性嗜铬细胞瘤和副神经节瘤中的一种可靶向受体酪氨酸激酶：安罗替尼的未来征程？
J Endocr Soc. 2024 May 7;8(7):bvae092. doi: 10.1210/jendso/bvae092. eCollection 2024 May 23.
2
Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.安罗替尼用于转移性进展性嗜铬细胞瘤和副神经节瘤：真实世界数据的回顾性研究
J Endocr Soc. 2024 Apr 2;8(6):bvae061. doi: 10.1210/jendso/bvae061. eCollection 2024 Apr 6.
3
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.安罗替尼对比舒尼替尼作为转移性肾细胞癌一线治疗的随机 II 期临床试验。
Oncologist. 2019 Aug;24(8):e702-e708. doi: 10.1634/theoncologist.2018-0839. Epub 2019 Mar 22.
4
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.安罗替尼：一种新型多靶点酪氨酸激酶抑制剂的临床开发。
J Hematol Oncol. 2018 Sep 19;11(1):120. doi: 10.1186/s13045-018-0664-7.
5
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.高度强效且选择性的血管内皮生长因子受体-2抑制剂安罗替尼的临床前特征
Cancer Sci. 2018 Apr;109(4):1207-1219. doi: 10.1111/cas.13536. Epub 2018 Mar 25.
6
Targeted Therapies in Pheochromocytoma and Paraganglioma.靶向治疗在嗜铬细胞瘤和副神经节瘤中的应用。
J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972. doi: 10.1210/clinem/dgac471.
7
Malignant pheochromocytoma and paraganglioma: management options.恶性嗜铬细胞瘤和副神经节瘤：治疗选择。
Curr Opin Oncol. 2020 Jan;32(1):20-26. doi: 10.1097/CCO.0000000000000589.
8
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].[基于近期科学进展的恶性嗜铬细胞瘤和副神经节瘤的抗血管生成治疗]
Pol Merkur Lekarski. 2015 Apr;38(226):191-5.
9
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.转移性嗜铬细胞瘤/副神经节瘤系统治疗反应：回顾性多中心队列研究。
Eur J Endocrinol. 2023 Nov 8;189(5):546-565. doi: 10.1093/ejendo/lvad146.
10
Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.131I-MIBG 与舒尼替尼联合治疗致 SDHB 突变的遗传性副神经节瘤-嗜铬细胞瘤综合征患者转移性副神经节瘤缓解
Clin Nucl Med. 2016 Mar;41(3):204-6. doi: 10.1097/RLU.0000000000000973.
本文引用的文献
1
Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.安罗替尼用于转移性进展性嗜铬细胞瘤和副神经节瘤：真实世界数据的回顾性研究
J Endocr Soc. 2024 Apr 2;8(6):bvae061. doi: 10.1210/jendso/bvae061. eCollection 2024 Apr 6.
2
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.舒尼替尼用于转移性进展性嗜铬细胞瘤和副神经节瘤：来自FIRSTMAPPP的结果，一项学术性、多中心、国际性、随机、安慰剂对照、双盲的2期试验
Lancet. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0. Epub 2024 Feb 22.
3
Targeted Therapies in Pheochromocytoma and Paraganglioma.靶向治疗在嗜铬细胞瘤和副神经节瘤中的应用。
J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972. doi: 10.1210/clinem/dgac471.
4
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).过去 20 年（2001-2020 年）用于实体瘤的酪氨酸激酶抑制剂。
J Hematol Oncol. 2020 Oct 27;13(1):143. doi: 10.1186/s13045-020-00977-0.
5
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.帕唑帕尼用于晚期/进展性恶性嗜铬细胞瘤和副神经节瘤的II期试验。
Endocrine. 2017 Aug;57(2):220-225. doi: 10.1007/s12020-017-1359-5. Epub 2017 Jul 6.
6
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.舒尼替尼引起的高血压与循环内皮素-1 水平升高有关。
Hypertension. 2010 Oct;56(4):675-81. doi: 10.1161/HYPERTENSIONAHA.109.149690. Epub 2010 Aug 23.
7
Imatinib as a paradigm of targeted therapies.伊马替尼作为靶向治疗的范例。
Adv Cancer Res. 2004;91:1-30. doi: 10.1016/S0065-230X(04)91001-9.
Zotero 插件